Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Turn Therapeutics.

    Client Virtual Booth

    TURN THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Turn Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Calabasas, CA
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://turntherapeutics.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Turn Therapeutics Invites Investment for Wound Formula Expansion into Eczema

    Details:

    The proceeds will fund clinical trials of its FDA-cleared antimicrobial ointment for two potential new drug indications: moderate to severe eczema and onychomycosis, or toenail fungus.


    Lead Product(s): Undisclosed

    Therapeutic Area: Dermatology Product Name: Undisclosed

    Highest Development Status: IND EnablingProduct Type: Undisclosed

    Partner/Sponsor/Collaborator: Undisclosed

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Financing May 22, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Turn Therapeutics Receives Authorization to Commence Human Trial for COVID-19 Therapeutic Candidate

    Details:

    Hexagen contains broad-spectrum, liquid antimicrobials with strong antiviral activity suspended in petrolatum. The trial will assess Hexagen’s ability to prevent COVID-19 infection in frontline workers when worn intranasally as an adjunct to personal protective equipment.


    Lead Product(s): Petrolatum

    Therapeutic Area: Infections and Infectious Diseases Product Name: Hexagen

    Highest Development Status: UndisclosedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 21, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    farmak-a-s-m-2024-08-26

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search